Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of SAWAI GROUP HOLDINGS Co., Ltd.. A complete text table follows the diagram.
Core operating profit still rose 9.5%, revealing a JPY5.2B gap between underlying generics growth and IFRS earnings.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Cardiovascular | 1 | 22.9B | 23.2% of reported total |
| Central nervous system | 1 | 13.9B | 14.1% of reported total |
| Other metabolic | 1 | 11.5B | 11.7% of reported total |
| Digestive system | 1 | 11.2B | 11.3% of reported total |
| Blood & body fluids | 1 | 10.2B | 10.3% of reported total |
| Other therapies | 1 | 6.7B | 6.8% of reported total |
| Antibiotics | 1 | 5.1B | 5.2% of reported total |
| Allergy | 1 | 3.9B | 4.0% of reported total |
| Respiratory | 1 | 3.8B | 3.8% of reported total |
| Vitamins | 1 | 3.6B | 3.7% of reported total |
| Oncology | 1 | 3.2B | 3.3% of reported total |
| Genitourinary | 1 | 2.7B | 2.7% of reported total |
| Gross revenue by therapeutic class | 2 | 98.8B | Reported six-month total · ¥98.8B |
| Revenue by therapeutic class | 3 | 98.8B | Reported consolidated total |
| Eliminations & reconciliation | 3 | 1M | Reported dimensional reconciliation |
| Operating profit | 4 | 8.5B | 8.6% operating margin |
| Operating costs & expenses | 4 | 90.3B | Arithmetic residual to reported operating profit |
| Profit before tax | 5 | 8.0B | Reported pretax result |
| Net non-operating cost | 5 | 572M | Arithmetic bridge to reported pretax profit |
| Net profit attributable to owners | 6 | 5.8B | Reported parent-company result |
| Tax, attribution & other | 6 | 2.1B | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Cardiovascular | Gross revenue by therapeutic class | 22.9B |
| Central nervous system | Gross revenue by therapeutic class | 13.9B |
| Other metabolic | Gross revenue by therapeutic class | 11.5B |
| Digestive system | Gross revenue by therapeutic class | 11.2B |
| Blood & body fluids | Gross revenue by therapeutic class | 10.2B |
| Other therapies | Gross revenue by therapeutic class | 6.7B |
| Antibiotics | Gross revenue by therapeutic class | 5.1B |
| Allergy | Gross revenue by therapeutic class | 3.9B |
| Respiratory | Gross revenue by therapeutic class | 3.8B |
| Vitamins | Gross revenue by therapeutic class | 3.6B |
| Oncology | Gross revenue by therapeutic class | 3.2B |
| Genitourinary | Gross revenue by therapeutic class | 2.7B |
| Gross revenue by therapeutic class | Revenue by therapeutic class | 98.8B |
| Gross revenue by therapeutic class | Eliminations & reconciliation | 1M |
| Revenue by therapeutic class | Operating profit | 8.5B |
| Revenue by therapeutic class | Operating costs & expenses | 90.3B |
| Operating profit | Profit before tax | 8.0B |
| Operating profit | Net non-operating cost | 572M |
| Profit before tax | Net profit attributable to owners | 5.8B |
| Profit before tax | Tax, attribution & other | 2.1B |